Spontaneous reports of adverse events are a core source of information. They offer a unique, unrestricted perspective on drug performance. ...

Cancer is often viewed as one monolithic disease, but every cancer is unique. Therapies with accurate diagnosis are needed to effectively fight the disease ...

Biases and heterogeneity in the data of spontaneous adverse event reporting systems can make it hard to gain the insights to inform decisions. ...

Despite growing scientific insight and technological investment, attempts to develop novel therapies still show limited success. ...

With increased focus on literature monitoring, pharmacovigilance groups must analyze existing processes to achieve efficiencies and maintain compliance. ...

Biological researchers face growing body of scientific literature that they must search through in order to keep up with developments in their field. ...

Preclinical safety programs often follow a standard template to determine off-target effects. ...

With the growing number of high-profile safety-related drug withdrawals and the increasing consumer expectations of drug safety. ...

The scope of what pharmacovigilance leaders must consider has greatly increased as regulatory agencies worldwide have broadened their expectations. ...

Practical steps that pharmacovigilance leaders should take in order to achieve and maintain global oversight of their pharmacovigilance process. ...

Technological advances in the retrieval and assessment of data have enabled a straightforward and elegant means to create predictive models of compound. ...

There is no room for error when it comes to pharmacovigilance. The FDA and EMA expect 100% of adverse drug reactions to be found in the literature ...

Precision medicines display high efficacies against their target groups, but they still face the same problems as other drugs: high attrition rates ...

Since the early 1990s, R&D expenditure by U.S. pharmaceutical companies has grown exponentially, but not because more drugs are being produced and approved ...

Antibody-drug conjugates, or ADCs, are a class of exciting new therapeutics that utilize the patient’s own immune system, with the antibody ...